AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33225901
Drug: FDA-approved immune
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA-approved immune checkpoint inhibitors (ICIs)
Trial: 35714551
Drug: Methylphenidate (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (continued treatment for 7 weeks)
Trial: 34929355
Drug: Wii therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wii therapy (interactive gaming, Nintendo Wii)
Trial: 32572617
Drug: EX +
RxNorm normalized name: Freeflex + Transfer Adapter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EX + PRO (30 min low-moderate-intensity treadmill walking followed by 20 g whey protein)
Trial: 33433386
Drug: FA-TiO2-Pc (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FA-TiO2-Pc (low dose)
Trial: 35236735
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg olanzapine (OLZ) in combination with triple antiemetic therapy
Trial: 35236735
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with triple antiemetic therapy
Trial: 32202716
Drug: Xiao's 'xingnaofusu'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiao's 'xingnaofusu' needling and routine western medicine
Trial: 35911085
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) <1 year after diagnosis
Trial: 32975189
Drug: 5% imiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% imiquimod cream (Aldara) for up to 16 weeks
Trial: 32975189
Drug: 0.15% podophyllotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% podophyllotoxin cream (Warticon) for 4 weeks (extended to 16 weeks if warts persisted)
Trial: 32975189
Drug: Quadrivalent human
RxNorm normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent human papillomavirus vaccine (Gardasil)
Trial: 32975189
Drug: Saline control
RxNorm normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline control (placebo for HPV vaccine)
Trial: 32975189
Drug: 5% imiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% imiquimod cream (Aldara)
Trial: 32975189
Drug: 0.15% podophyllotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% podophyllotoxin cream (Warticon)
Trial: 32882244
Drug: Balanced crystalloids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced crystalloids (lactated Ringer's solution or Plasma‐Lyte A)
Trial: 36178015
Drug: Multifaceted optimization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted optimization management (integration of usual care and traditional Chinese medicine treatment)
Trial: 34990772
Drug: L-Citrulline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Citrulline (6 g/day)
Trial: 34878335
Drug: Flow cytometry-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flow cytometry-based antibiotic susceptibility testing (MICy)
Trial: 35383975
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (Lactobacillus and Bifidobacterium spp)
Trial: 35383975
Drug: Oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metronidazole (MET)
Trial: 32694215
Drug: Albiglutide +
RxNorm normalized name: Albiglutide
DrugBank: Albiglutide (DB09043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albiglutide + optimized basal insulin glargine and lispro (dose reduced by 50% at randomization; lispro injections fully discontinued 4 weeks later)
Trial: 34764501
Drug: Isobaric levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric levobupivacaine (0.5%, 0.3-0.4 mg/kg)
Trial: 34764501
Drug: Isobaric ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric ropivacaine (0.5%, 0.5 mg/kg)
Trial: 34106357
Drug: Robot-assisted Pivotal
RxNorm normalized name: PIVOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted Pivotal Response Treatment (PRT + robot)
Trial: 33069784
Drug: Endothelial function
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelial function guided treatment group
Trial: 33872825
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants (DOACs) prescribed by PCPs
Trial: 34191028
Drug: Daily meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily meal with 1 fresh Hass avocado
Trial: 32871530
Drug: High-intensity light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity light therapy (LT-5000 lux)
Trial: 32871530
Drug: Low-intensity light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity light therapy (LT-500 lux)
Trial: 35954937
Drug: Physiologic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic saline solution (placebo)
Trial: 34268638
Drug: Slowness therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slowness therapy (weekly speech therapy sessions with stimuli played slowly on a PC)
Trial: 34268638
Drug: Real-time stimuli
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time stimuli speech therapy (age- and level-matched control group)
Trial: 34111616
Drug: Manipulation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulation of gut bacteria (via FMT or antibiotics)
Trial: 36102337
Drug: Cocoa extract
RxNorm normalized name: Cocoa extract
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa extract (500 mg/day flavanols)
Trial: 33159574
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 (menaquinone-7) 180 µg twice a day for 12 weeks
Trial: 33228575
Drug: Aripiprazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (15 mg orally)
Trial: 33228575
Drug: Aripiprazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (15 mg orally) with abnormally low prolactin levels
Trial: 33228575
Drug: Aripiprazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (15 mg orally) without abnormally low prolactin levels
Trial: 32302504
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 (5 μg/day for 100 days)
Trial: 32302504
Drug: Standard supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard supplementation (350 mg/day ferrous iron, 5 mg folic acid)
Trial: 33064182
Drug: Metformin (1700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1700 mg daily)
Trial: 33189805
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of airway strategies
Trial: 33189370
Drug: Group D
RxNorm normalized name: Prostaglandin group D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D - 30 mL of 0.5% levobupivacaine with vasoconstrictor and 6 mg (1.5 mL) of dexamethasone
Trial: 33189370
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C - 30 mL of 0.5% levobupivacaine with vasoconstrictor and 1.5 mL of 0.9% saline
Trial: 33172907
Drug: Medication-related problems
RxNorm normalized name: Psoriasin Problem Skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-related problems
Trial: 33727522
Drug: 0.075 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075 mg/kg oxycodone (Group A)
Trial: 33727522
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg oxycodone (Group B)
Trial: 33727522
Drug: 0.125 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg/kg oxycodone (Group C)
Trial: 33727522
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and 0.075 mg/kg oxycodone (Group A)
Trial: 33727522
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and 0.1 mg/kg oxycodone (Group B)
Trial: 33727522
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and 0.125 mg/kg oxycodone (Group C)
Trial: 35636580
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment (Phase 1)
Trial: 32064596
Drug: Topical calcitriol
RxNorm normalized name: calcitriol Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical calcitriol 0.0003%
Trial: 32064596
Drug: Topical rapamycin-calcitriol
RxNorm normalized name: calcitriol Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical rapamycin-calcitriol combination
Trial: 35294537
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg orally twice daily for 10 days
Trial: 34298398
Drug: ω-3 polyunsaturated
RxNorm normalized name: OMEGA-3 POLYUNSATURATES
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω-3 polyunsaturated fatty acid treatment
Trial: 32502876
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (1.8 mg/kg once every 3 weeks; ≤16 cycles)
Trial: 37150125
Drug: Probiotic capsules
RxNorm normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic capsules (Bifidobacterium bifidum BGN4 and Bifidobacterium longum BORI)
Trial: 33068425
Drug: Hydroxychloroquine once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine once-weekly (400 mg)
Trial: 33068425
Drug: Hydroxychloroquine twice-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine twice-weekly (400 mg)
Trial: 32525564
Drug: High-intensity interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity interval training (HIIT) during cisplatin-based chemotherapy (CBCT) for testicular cancer (TC). The intervention included two weekly HIIT sessions, each with 2 to 4 intervals of 2 to 4 minutes at 85% to 95% of peak heart rate for 9 to 12 weeks.
Trial: 34152632
Drug: Hemoadsorption (HA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoadsorption (HA) therapy
Trial: 35713873
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 300 U/mL (Gla-300)
Trial: 32243043
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec 100 U/mL (IDeg-100)
Trial: 36263928
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 300 U/mL (Gla-300) and Insulin degludec 100 U/mL (IDeg-100)
Trial: 33278503
Drug: Low-dose whole-lung
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose whole-lung irradiation (LD-WLI) 0.5 Gy
Trial: 33278503
Drug: Low-dose whole-lung
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose whole-lung irradiation (LD-WLI) 1.0 Gy
Trial: 33278503
Drug: Low-dose whole-lung
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose whole-lung irradiation (LD-WLI) overall
Trial: 39669005
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injections
Trial: 33465795
Drug: Melissa Officinalis
RxNorm normalized name: melissa officinalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melissa Officinalis L. (500 mg daily)
Trial: 36121830
Drug: Systematic medication
RxNorm normalized name: Integrase Inhibitors, antiinfectives for systematic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic medication review conducted by pharmacists during the emergency department stay
Trial: 35278124
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg etifoxine
Trial: 35278124
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg alprazolam
Trial: 35710124
Drug: Guided internet
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet based cognitive behavioural therapy (CBT‐TF) with an eight step online programme, up to three hours of contact with a therapist, and four brief telephone calls or email contacts between sessions.
Trial: 35710124
Drug: Guided internet
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet based cognitive behavioural therapy (CBT‐TF)
Trial: 35710124
Drug: Individual face‐to‐face
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual face‐to‐face cognitive behavioural therapy (CBT‐TF)
Trial: 34936159
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of traditional lecture and mobile application
Trial: 35576534
Drug: Carbohydrate drink
RxNorm normalized name: Ensure Pre-Surgery Clear Carbohydrate Drink (Strawberry)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate drink (CHO) group received 400 mL of a carbohydrate drink 2 to 3 hours before anesthesia
Trial: 34919684
Drug: Con+BM (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Con+BM (control treatment consisting of placebo and basic care micronutrient mixture)
Trial: 32894558
Drug: Myo-inositol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myo-inositol (2 g), Alpha-Lactalbumin (50 mg), folic acid (200 µg) every morning for 6 months; Myo-inositol (600 mg), melatonin (1 mg), folic acid (200 µg) in the evening for 3 months before oocyte pick up; Myo-inositol (600 mg), folic acid (200 µg), melatonin (1 mg), vitamin D3 (50 µg) until the 12th week of gestation
Trial: 32894558
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated with 200 µg folic acid twice a day
Trial: 36145188
Drug: Enzobiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzobiotic therapy (synbiotics and proteolytic enzymes) over 12 weeks
Trial: 35265960
Drug: 24 g
RxNorm normalized name: glucose 24 g/31 g oral gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 g whole dragon fruit powder (33 mg betalains)
Trial: 32811539
Drug: Goal-directed human
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed human albumin substitution aimed at a concentration > 30 g/l during surgery and postanesthesia care unit stay.
Trial: 34958693
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 4-hexylresorcinol (4-HR) and niacinamide
Trial: 33482797
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (5 ml of 2.5% sodium hypochlorite, followed by 5 ml of 17% EDTA and 5 ml of distilled water)
Trial: 35965169
Drug: Remotely-administered resilience-
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remotely-administered resilience- and wisdom-focused intervention (6 once-a-week one-hour sessions)
Trial: 35306660
Drug: Resistant dextrin
RxNorm normalized name: wheat dextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant dextrin (10 g day‐1 for 8 weeks)
Trial: 616782991
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine pattern-based clinical nursing care
Trial: 33637348
Drug: VB-111 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VB-111 and weekly paclitaxel 80 mg/m2
Trial: 33637348
Drug: Post-treatment fever
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment fever
Trial: 32726528
Drug: Nirsevimab (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nirsevimab (50 mg, single intramuscular injection)
Trial: 34880671
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine infusion during intraoperative period and 72 postoperative hours
Trial: 34880671
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion at the same volume, infusion rate, and timing
Trial: 34773928
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral relapse prevention therapy (RP)
Trial: 36085294
Drug: CBD-rich cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD-rich cannabis treatment for 6 months
Trial: 32249112
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of ready-to-use therapeutic foods (RUTF)
Trial: 32249112
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose of ready-to-use therapeutic foods (RUTF)
Trial: 32249112
Drug: Both arms
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both arms (Standard and Reduced dose of RUTF)
Trial: 32249112
Drug: Standard and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard and Reduced dose of RUTF
Trial: 32555047
Drug: Ibuprofen (NSAID)
RxNorm normalized name: IBUPROFEN 200 mg ORAL TABLET [IBUPROFEN (NSAID) PAIN RELEIVER/ FEVER REDUCER]
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen (NSAID)
Trial: 36036648
Drug: Early rhythm
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early rhythm control (ERC) therapy
Trial: 33742603
Drug: 650 mg
RxNorm normalized name: bran 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg of decaffeinated green tea extract (dGTE) for 4 weeks
Trial: 33068157
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 (360 µg daily for 6 months)
Trial: 33369020
Drug: PRT +
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PRT + ProD (whey protein 20 g each morning plus 20 g postexercise and vitamin D3 2000 IU/day)
Trial: 36181108
Drug: Antibiotics combined
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics combined with mucosolvan perfusion therapy under fiber bronchoscope
Trial: 36181108
Drug: Antibiotics combined
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics combined with mucosolvan lavage therapy under fiber bronchoscope
Trial: 33263644
Drug: Oseltamivir (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (75 mg orally twice daily for 5 days)
Trial: 33263644
Drug: Zanamivir (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanamivir (10 mg inhaled twice daily for 5 days)
Trial: 34076770
Drug: Inside-stent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inside-stent therapy
Trial: 34076770
Drug: Conventional-stent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-stent therapy
Trial: 34076770
Drug: Inside-stent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inside-stent therapy as second stent
Trial: 36102002
Drug: Centrifugation (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centrifugation (30 min daily)
Trial: 35227041
Drug: G-premio Bond
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-premio Bond
Trial: 34206160
Drug: iodine‐reduced kelp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iodine‐reduced kelp powder (6 g kelp powder corresponding to 3 g alginate/d)